Prostate cancer is the only cancer for which no reliable imaging modality exists for the detection of localized disease. There are over 2.3 Million men in the U.S. with prostate cancer and over 3 Million ultrasounds and biopsies performed every year. Prostate cancer results in 30,000 deaths per year in the U.S. alone – second only to lung cancer.
Imagistx is the World's only ultra-high frequency ultrasound product for the prostate. Imagistx high resolution ultrasound system allows urologists to see the exquisite details of the prostate, allowing for better diagnosis, surveillance and treatment.
Initial clinical study at the John Hopkins Urology Center showed a 73% improvement in the detection of prostate cancer, a quantum leap over the current standard of care. Imagistx is now running a multi-site 960-patient clinical study that will statistically prove the superiority of
the system against the standard of care and drive up adoption.